Evidence map›Paper›PMID 37106259›Full record

SynthesisJournal of neurology2023

Antiplatelet therapy may improve the prognosis of patients with moyamoya disease: a 12-year retrospective study.

Yuting Luo, Zhixin Cao, Heng Ye, Shaoqing Wu, Xunsha Sun

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yuting Luo *Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, Guangzhou, 510080, China.
Zhixin Cao *Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, Guangzhou, 510080, China.
Heng YeDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, Guangzhou, 510080, China.
Shaoqing WuGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. wsqone@163.com.
Xunsha SunDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, Guangzhou, 510080, China. sunxsh3@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-4018-4188
Sun Yat-sen University · CNGuangzhou Women and Children Medical Center · CN

Funding

China-Sri Lanka Joint Center for Research and Education 2015B050501003China-Sri Lanka Joint Center for Research and Education 2020A0505020004Guangdong Provincial Clinical Research Center for Neurological Diseases 2020B1111170002Guangdong Provincial Engineering Center for Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, Guangzhou Clinical Research and Translational Cente 201604020010Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases 2020B1212060017Kelin New Talent Program R08016Natural Science Foundation of Guangdong Province for Distinguished Young Scholars 2016A030310139Science and Technology Projects in Guangzhou 202201020652the Fundamental Research Funds for the Central Universities 20ykpy66the National Natural Science Foundation of China 81102248the National Natural Science Foundation of China 81601004the National Natural Science Foundation of China 82071292the National Natural Science Foundation of China 82271333
6 · The paper itself

Abstract

objectivesThe clinical value of antiplatelet therapy (APT) for moyamoya disease (MMD) remains controversial. Our study attempts to clarify the value of APT in this disease.

methodsWe collected basic information, treatment strategies, and prognostic information on patients with MMD from 2010 to 2022 at our center. The data were divided into two groups, depending on whether APT was used or not, and compared by Pearson Chi-Square, Fisher's exact test, or Wilcoxon rank-sum test. We used propensity scores or inverse probability of treatment weighting to balance the covariates. Following this, we performed a meta-analysis of APT use in MMD.

results177 patients were enrolled, with a median follow-up of 41.1 months. APT did not affect the prognosis of patients with perioperative MMD, ischemic MMD, or asymptomatic MMD (P > 0.05), without increasing cerebral hemorrhagic risk. In contrast, APT was found to reduce mortality among patients with hemorrhagic MMD (P = 0.019), without affecting functional status, increasing stroke risk, or causing intracerebral hemorrhage (P > 0.05). But the small group cannot show the effect of APT. Our meta-analysis included nine articles involving 28,925 patients with MMD. It showed that APT could reduce stroke risk (odds ratio, OR = 0.57, 95% CI 0.49 to 0.65) and the Modified Rankin Scale (mRS) (weighted mean difference, WMD = - 0.07, 95% CI 0.14-0.00) during follow-up. The cohort study has limited weight (1.97% and 19.29%) in the meta-analysis.

conclusionAlthough the limited number of included documents, APT could be beneficial to the prognosis of MMD.

Indexed as

Moyamoya DiseaseStrokeCerebral HemorrhageCohort StudiesHumansPlatelet Aggregation InhibitorsPrognosisRetrospective StudiesTreatment OutcomePlatelet Aggregation InhibitorsAntiplatelet therapyMoyamoya diseasePrognosis

Identifiers

PMID37106259
OpenAlexW4367173307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.